Inflation Reduction Act Undermines Cancer Medicine Development
WASHINGTON, June 1, 2023 /PRNewswire/ — Today, the Pharmaceutical Research and Manufacturers of American (PhRMA) is highlighting a new analysis from Partnership for Health Analytic Research (PHAR) that demonstrates how the price setting provisions in the Inflation Reduction Act (IRA) acutely impact the research and development (R&D) of cancer medicines. Timing of post-approval indications Types … Read more